Table 2 Comparison of main TEAEs between different doses of lasmiditan and placebo
Outcome or Subgroup | Studies | Participants | Risk Ratio (M-H, Fixed, 95% CI) | P | I2 |
|---|---|---|---|---|---|
Dizziness | 4 | 7125 | 5.81 [4.72, 7.14] | <0.00001 | 67% |
<50 mg | 1 | 130 | 1.75 [0.77, 3.99] | 0.18 | / |
50 mg | 2 | 1467 | 4.55 [2.70, 7.67] | <0.00001 | 70% |
100 mg | 3 | 2695 | 5.75 [4.10, 8.06] | <0.00001 | 69% |
200 mg | 3 | 2677 | 6.59 [4.72, 9.21] | <0.00001 | 57% |
400 mg | 1 | 156 | 64.94 [4.03, 1047.06] | 0.003 | / |
Nausea | 3 | 6995 | 2.58 [1.87, 3.57] | <0.00001 | 0% |
50 mg | 2 | 1467 | 2.63 [1.20, 5.75] | 0.45 | 0% |
100 mg | 3 | 2695 | 2.37 [1.42, 3.94] | 0.0009 | 41% |
200 mg | 3 | 2677 | 2.54 [1.54, 4.21] | 0.0003 | 0% |
400 mg | 1 | 156 | 13.48 [0.76, 239.65] | 0.08 | / |
Fatigue | 4 | 7125 | 5.38 [3.78, 7.66] | <0.00001 | 29% |
<50 mg | 1 | 130 | 1.19 [0.40, 3.58] | 0.75 | / |
50 mg | 2 | 1467 | 3.52 [1.62, 7.64] | 0.001 | 0% |
100 mg | 3 | 2695 | 6.99 [3.62, 13.48] | <0.00001 | 0% |
200 mg | 3 | 2677 | 6.77 [3.51, 13.07] | <0.00001 | 0% |
400 mg | 1 | 156 | 9.83 [2.34, 41.31] | 0.002 | / |
Paraesthesia | 4 | 7125 | 4.48 [3.33, 6.02] | <0.00001 | 13% |
<50 mg | 1 | 130 | 20.78 [1.29, 334.92] | 0.03 | / |
50 mg | 2 | 1467 | 2.24 [0.98, 5.14] | 0.06 | 0% |
100 mg | 3 | 2695 | 3.90 [2.43, 6.26] | <0.00001 | 21% |
200 mg | 3 | 2677 | 5.03 [3.17, 7.99] | <0.00001 | 0% |
400 mg | 1 | 156 | 8.60 [2.02, 36.58] | 0.004 | / |
Somnolence | 3 | 6995 | 2.82 [2.18, 3.66] | <0.00001 | 0% |
50 mg | 2 | 1467 | 2.86 [1.60, 5.09] | 0.04 | 0% |
100 mg | 3 | 2695 | 2.59 [1.70, 3.95] | <0.00001 | 0% |
200 mg | 3 | 2677 | 2.92 [1.92, 4.42] | <0.00001 | 0% |
400 mg | 1 | 156 | 4.91 [1.08, 22.40] | 0.0004 | / |